- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ipsen SA ADR (IPSEY)
Ipsen SA ADR stock price live, this page displays OTC IPSEY stock exchange data. View the IPSEY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ipsen SA ADR real time stock price chart below.
What Is the Ipsen SA ADR Stock Price Today?
The Ipsen SA ADR stock price today is 31.140.
What Is the Stock Symbol for Ipsen SA ADR?
The stock symbol for Ipsen SA ADR is ""IPSEY.""
What Stock Exchange Does Ipsen SA ADR Trade On?
Ipsen SA ADR is listed and trades on the OTC Markets stock exchange.
Is Ipsen SA ADR a Good Stock to Buy?
Determining whether Ipsen SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPSEY quote. (ISIN: US4626292050)
What Is the Ipsen SA ADR Stock Price Today?
The Ipsen SA ADR stock price today is 31.140.
What Is the Stock Symbol for Ipsen SA ADR?
The stock symbol for Ipsen SA ADR is ""IPSEY.""
What Stock Exchange Does Ipsen SA ADR Trade On?
Ipsen SA ADR is listed and trades on the OTC Markets stock exchange.
Is Ipsen SA ADR a Good Stock to Buy?
Determining whether Ipsen SA ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IPSEY quote. (ISIN: US4626292050)
31.140
0.000(0.00%)
Delayed Data·
Fair Value
An estimate of a Ipsen ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.140
31.140
52 wk Range
25.110
33.000
IPSEY Scorecard
Full Analysis
Net income is expected to grow this year
IPSEY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Ipsen ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.14031.140
52 wk Range
25.11033.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.93%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.93%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPSEY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Ipsen ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
- Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Ipsen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Sutro Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Ipsen SA ADR Company Profile
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Compare IPSEY to Peers and Sector
Metrics to compare | IPSEY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPSEYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 19.7x | 22.8x | −0.5x | |
PEG Ratio | −0.58 | 0.11 | 0.00 | |
Price/Book | 2.1x | 3.7x | 2.6x | |
Price / LTM Sales | 2.3x | 2.2x | 3.3x | |
Upside (Analyst Target) | - | 1.2% | 41.6% | |
Fair Value Upside | Unlock | 17.6% | 5.9% | Unlock |
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
4.00 / --
Revenue / Forecast
1.03B / 1.08B
FAQ
What Stock Exchange Does Ipsen ADR Trade On?
Ipsen ADR is listed and trades on the OTC Markets stock exchange.
What Is the Stock Symbol for Ipsen ADR?
The stock symbol for Ipsen ADR is "IPSEY."
What Is the Ipsen ADR Market Cap?
As of today, Ipsen ADR market cap is 10.56B.
What Is Ipsen ADR's Earnings Per Share (TTM)?
The Ipsen ADR EPS (TTM) is 5.42.
When Is the Next Ipsen ADR Earnings Date?
Ipsen ADR will release its next earnings report on 21 Oct 2025.
From a Technical Analysis Perspective, Is IPSEY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Ipsen ADR Stock Split?
Ipsen ADR has split 0 times.
How Many Employees Does Ipsen ADR Have?
Ipsen ADR has 5358 employees.
What is the current trading status of Ipsen ADR (IPSEY)?
As of 13 Aug 2025, Ipsen ADR (IPSEY) is trading at a price of 31.14, with a previous close of 31.14. The stock has fluctuated within a day range of 31.14 to 31.14, while its 52-week range spans from 25.11 to 33.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.